Doxorubicin HCI

Rubicin®

Prescription Drug

Indication

Doxorubicin has been used successfully both as a single agent and also in combination with other cancer chemotherapeutic agents in a number of solid tumors and hematologic malignancies such as:

• Acute lymphocytic-lymphoblastic leukemias
• Acute myeloblastic leukemia
• Wilm’s tumor
• Neuroblastoma
• Soft tissue sarcomas
• Osteosarcoma
• Breast carcinoma
• Ovarian carcinoma
• Thyroid carcinoma
• Gastric carcinoma
• Malignant lymphoma
• Hodgkin’s disease
• Non-Hodgkin’s lymphoma
• Transitional cell bladder carcinoma
• Bronchogenic carcinoma in which the small cell histologic type is the most responsive
• Squamous cell carcinoma of the head and neck

Doxorubicin has also shown antitumor activity in the following adult and pediatric malignancies:

• Endometrial carcinoma
• Primary hepatocellular carcinoma
• Non-seminomatous carcinoma of the testis
• Carcinoma of the prostate
• Ewing’s sarcoma
• Rhabdomyosarcoma
• Multiple myeloma
• Chronic leukemias

Doxorubicin has also been used for the following:

• As a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer
• By instillation into the bladder for the topical treatment of superficial bladder tumors

Dosage and Administration

For more information on safety, precaution and other information about this product, please see the Product Insert.